4-Amino-6-benzylamino-1,2-dihydro-2-phenyl-1,2,4-triazolo [4,3-alpha]-quinoxalin-1-one: a new A2A adenosine receptor antagonist with high selectivity versus A1 receptors.
Colotta
V
V
Dipartimento di Scienze Farmaceutiche, Università di Firenze, Italy.
Catarzi
D
D
Varano
F
F
Cecchi
L
L
Filacchioni
G
G
Martini
C
C
Trincavelli
L
L
Lucacchini
A
A
D000818:Animals; D001665:Binding Sites; D002417:Cattle; D058915:Purinergic P1 Receptor Antagonists; D011743:Pyrimidines / Q000378:metabolism / Q000494:pharmacology; D011810:Quinoxalines / Q000138:chemical synthesis* / Q000378:metabolism / Q000494:pharmacology; D043705:Receptor, Adenosine A2A; D018047:Receptors, Purinergic P1 / Q000378:metabolism; D013329:Structure-Activity Relationship; D014230:Triazoles / Q000138:chemical synthesis* / Q000378:metabolism / Q000494:pharmacology
C118526:4-amino-6-benzylamino-1,2-dihydro-2-phenyl-1,2,4-triazolo(4,3-a)-quinoxalin-1-one; C098657:5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine; D058915:Purinergic P1 Receptor Antagonists; D011743:Pyrimidines; D011810:Quinoxalines; D043705:Receptor, Adenosine A2A; D018047:Receptors, Purinergic P1; D014230:Triazoles